NVL-520-01: A Phase 1/2 study of the highly selective ROS1 inhibitor NUV-520 in patients with advanced NSCLC and other solid tumors (ARROS-1).

Brief description of study

You can participate in this study if you are diagnosed with advanced non-small cell lung cancer, and other advanced solid cancers. The purpose of this study is to determine the safety and tolerability of NVL-520 (anti-cancer drug) in the treatment of non-small cell lung cancer, and in advanced solid tumors, who have experienced treatment failure after clinical standard of care treatments or who currently have no effective treatment available to evaluate the safety, and tolerability. This study also determines how the study drug is absorbed in the body, broken down by the body, circulated in the body, and passed out of the body. The patients will be monitored and taken care of while on this medication during the entire study period.


Clinical Study Identifier: s22-00366
ClinicalTrials.gov Identifier: NCT05118789
Principal Investigator: Vamsidhar Velcheti.
Other Investigators: Samantha VanMaanen, Carol M Lee, Salman Rafi Punekar, Elaine Shum, Jessica Wang, Sally Lau, Gabrielle Fridman, Joshua K Sabari, David Mendoza, Melissa L Martinez, Jonathan B Kahn, Natalia Cherkassky, Kirby Rodriguez.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.